Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.6M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Eledon Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 36 | 32 | −4 |
| Shares | 7.88M | 7.01M | −879.8K (−11.2%) |
| Value | $34.7M | $27.6M | −$7.15M (−20.6%) |
New holders (2)
Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bailard, Inc. | 27,600 | $109.0K | 0.00% |
| IFP Advisors, Inc | 1 | – | – |
Sold out (6)
Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Logos Global Management LP | 1,339,793 | $5.91M |
| FMR LLC | 504,371 | $2.22M |
| Ameritas Advisory Services, LLC | 24,219 | $107.0K |
| Citadel Advisors LLC | 10,174 | $45.0K |
| UBS Group AG | 3,638 | $16.0K |
| Bank of America Corp | 27 | $0 |